Orders Over $30 Unlock Free Shipping

Your cart

Your cart is empty

Check out these collections.

About Glyciome®

Glyciome, LLC is a women-owned, Spokane-based, bioscience start-up commercializing first-in-class urogenital healthcare products. Our patent-pending therapeutics treat common genital infections and inflammation that contribute to genital carcinogenesis (e.g., cancers of the cervix, uterus, ovaries, prostate and penis) through a “microbiota-cancer axis” (i.e., the oncobiome). Our founders have a unique understanding of genital ecosystem physiology which fosters development of breakthrough interventions with unparalleled efficacy and safety.

Our Mission

Glyciome is developing therapeutic drugs, medical devices, and personal care products that are changing genital care paradigms. Our products support healthy, human surface function across all ages. Genital infections more than double the risk of developing genital cancers. Our patent portfolio combines cuttingedge science in metabolomics, nanotechnology, and human-centered design-thinking, to meet the demands of a $26B/yr. global personal and genital healthcare market.

Our Cervical Cancer Prevention Technology

“PreBioGyn”, is an isotonic, intravaginal, hydrogel - targeted to prevent cervical cancer, including for people in low resource settings (LRS) with poor healthcare access. These people are those most at risk of developing cervical cancer, the 4th most frequent female cancer worldwide, and a U.S. demographic currently experiencing a “staggering rise” in death rates from this cancer.

Our $454,968 NCI Phase I STTR “Cervical Cancer Prevention Prebiotic Device” was completed in late 2023, and funded under NOT-CA-21-062 (Cancer Prevention, Diagnosis, and Treatment Technologies for Low- Resource Settings, SBA approved waiver eligible topics). Glyciome is preparing a $2.25MM Phase II Renewal to continue gel translational research and commercial scale-up through an SBIR R43 Clinical Trial Required mechanism.

Our Related Technology Pipeline

  • Our direct-to-consumer (DTC) Wild & Pure® prebiotic, total-body cleansers (wildandpure.com) are used for skin and genital care across all ages. Wild & Pure* won the 2021 Idaho Innovation Award for Consumer Product of the Year. Our ‘Natural’ version is EWG-verified® which assure consumers of the rigorous scientific review these products have undergone to meet the highest standards in safety.
  • Our near-market, kraft-paper vaginal applicator was developed during Phase I for PreBioGyn gel delivery and decreases waste and plastic contaminant exposure during gel application.
  • Our translational-stage related mobile app will monitor vaginal health and increase product-fit awareness for patients and providers during use of PreBioGyn and other vaginal products
  • Our early-stage, carbon nanotube biosensor is a rapid, user-directed diagnostic screen for bacterial vaginosis (BV), the most common of all vaginal infections.
Glyciome is uniquely positioned to revolutionize global women’s health, and grow bioscience business jobs in Spokane through commercialization of our disruptive technologies. Completed PreBioGyn Phase I studies provided significant de-risking and feasibility support for commercialization of our cervical cancer prevention gel.

    Glyciome’s Founders

    JE Ellington, PhD - Majority Owner/Founder & CEO

    Reproductive Physiologist and experienced entrepreneur. For three decades, she has invented and commercialized ground-breaking, reproductive-health related products (e.g. first FDA-cleared fertility lubricant, first paraben-free antepartum perineal massage gel). She holds over 15 issued patents. Her most successful product to date is Pre-Seed® Fertility Lubricant (licensed to Church & Dwight). Through her NIH-funded PI and CEO roles in several start-ups she has learned each step of the commercialization process. Dr. Ellington has extensive capability in messaging to federal agencies, Key Opinion Leaders, and consumers/patients. She has overseen three SBIR/STTR grants and completed the NIH ICORP training. She oversees our patent and grant development, scientific strategy, budget management, product design and marketing, and retail and wholesale sales.

    Dr. Clifton, PharmD - Owner/Founder, COO & Pharmaceutical Scientist

    Dr. Clifton has 20 years of experience in commercialization of reproductive healthcare products. He has played a key role in the bench to market transition of over 10 consumer products. Dr. Clifton’s experience includes pharmacy practice, clinical pharmacology research, and administration (e.g. Dept Chair & Interim Dean, WSU). He oversees our product formulation, production, biocompatibility testing, IRB & clinical study design/oversight, and regulatory & quality management. He has prepared and submitted numerous FDA 510(k) applications. His sales experience consists of successful pitch presentations and negotiations with large retail chains (e.g. CVS, Walgreens, Target).

    Our corporate business professional partners include Eide Bailly and Greenburg Traurig Law.


    April 2024: Glyciome Wins Grant Writing Assistance Award from HSSA